Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube Mar 11, 2026
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube Mar 11, 2026
Company Deals

J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion

Fineline Cube Feb 13, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care...

Company Deals

Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor

Fineline Cube Feb 13, 2025

China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...

Company Drug

Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management

Fineline Cube Feb 13, 2025

The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces...

Company Deals

AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies

Fineline Cube Feb 13, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...

Company Drug

Astellas Pharma’s Izervay Gets FDA Approval for GA Treatment Without Dosing Limit

Fineline Cube Feb 13, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the US Food and Drug Administration...

Company Deals

Andon Health to Fully Control iHealth by Acquiring Best Ventures’ Stake

Fineline Cube Feb 13, 2025

China-based Andon Health Co., Ltd (SHE: 002432) announced a plan to obtain the 20% stake...

Company

Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role

Fineline Cube Feb 13, 2025

Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...

Company Drug

Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease

Fineline Cube Feb 13, 2025

Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...

Company

J&J Innovative Medicine China Appoints New General Manager and Oncology VP

Fineline Cube Feb 13, 2025

Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...

Company Deals

Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder

Fineline Cube Feb 13, 2025

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual...

Company Drug

Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU

Fineline Cube Feb 13, 2025

Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...

Company Drug

Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA

Fineline Cube Feb 13, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...

Company Deals

Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform

Fineline Cube Feb 13, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...

Company Medical Device

Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval

Fineline Cube Feb 13, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the...

Company Deals

Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...

Company Deals Drug

Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases

Fineline Cube Feb 12, 2025

Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....

Company

Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology

Fineline Cube Feb 12, 2025

Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...

Company Drug

Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study

Fineline Cube Feb 12, 2025

Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...

Company Drug

Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US

Fineline Cube Feb 12, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug...

Company Deals

Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion

Fineline Cube Feb 12, 2025

China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...

Posts pagination

1 … 181 182 183 … 633

Recent updates

  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
  • Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
  • Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.